Clinical Trial Update: MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States [Phase 3]

View source ↗

Summary

Phase 3 trial of MEDI-524 (motavizumab) for RSV prevention in Native American infants completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Disease
• Respiratory Syncytial Virus Infection

Drugs mentioned

• MEDI-524

Snippet

Sponsor: MedImmune LLC | Conditions: Healthy | Phase 3 | Status: COMPLETED | Results posted: 2022-01-05